Icure acquires approval of Phase 3 clinical trial of donepezil patches for the first time

Icure, a pharmaceutical R&D company owning the original technology of the Transdermal Drug Delivery System(TDDS) and having the largest market share in the donepezil market, acquired approval for the Phase 3 clinical trial of donepezil patches from the Ministry of Food and Drug Safety.

According to the company, the Phase 3 clinical trial will be conducted in the beginning of this May after hav...